In a neonate with cholestasis, how do liver enzyme patterns (AST, ALT, alkaline phosphatase, gamma‑glutamyl transferase) differ between biliary atresia and the various types of progressive familial intrahepatic cholestasis (PFIC)?

Gamma-Glutamyl Transferase (GGT) is the Key Discriminator

The most critical enzyme pattern distinguishing biliary atresia from PFIC types is gamma-glutamyl transferase (GGT): biliary atresia presents with markedly elevated GGT, while PFIC types 1 and 2 characteristically show low or normal GGT levels, and PFIC type 3 shows elevated GGT. 1

Biliary Atresia Enzyme Pattern

Biliary atresia demonstrates:

• Markedly elevated GGT (typically >274.5 U/L has 90.6% sensitivity and 75.7% specificity) 2
• Elevated direct bilirubin (>46.2 µmol/L) 2
• Elevated total bile acids (>67.4 µmol/L) 2
• Elevated alkaline phosphatase 3
• Moderate transaminase elevation (AST/ALT)

The combination of high GGT, direct bilirubin, and total bile acids provides strong diagnostic accuracy for biliary atresia, with GGT showing the highest AUC of 0.893 2.

PFIC Type 1 and 2 Enzyme Pattern

Both PFIC1 (ATP8B1 mutations) and PFIC2 (ABCB11 mutations) share a distinctive low GGT cholestasis profile 1:

• Low or normal GGT (averaging 15 IU/L, distinctly contrasting with biliary atresia) 4
• Elevated serum transaminases (AST/ALT)
• Elevated bilirubin and bile acids
• Low or normal cholesterol (averaging 156 mg/dl) 4

Distinguishing PFIC1 from PFIC2

While both have low GGT, several features help differentiate them 5:

PFIC2 characteristics:

• Higher ALT levels (more hepatocellular injury)
• Markedly elevated alpha-fetoprotein
• Very low biliary bile acid concentration
• Higher tendency for neonatal cholestasis presentation
• Severe lobular lesions with giant hepatocytes on histology
• Earlier liver failure
• Risk of hepatocellular carcinoma
• Cholelithiasis
• Negative BSEP canalicular staining on immunohistochemistry

PFIC1 characteristics:

• Extrahepatic manifestations (diarrhea, pancreatitis, hearing deficits) 1
• Less severe hepatocellular injury
• Fibrosis without bile duct proliferation on histology
• No increased HCC risk

PFIC Type 3 Enzyme Pattern

PFIC3 (ABCB4 mutations) presents with a high GGT cholestasis pattern, making it biochemically similar to biliary atresia 1:

• Markedly elevated GGT (contrasting sharply with PFIC1/2)
• Elevated alkaline phosphatase
• Elevated transaminases
• Massive bile duct proliferation on histology (key histologic differentiator from biliary atresia)
• May have intrahepatic gallstones
• Often presents later in childhood (though can present in infancy)

Practical Diagnostic Algorithm

Step 1: Measure GGT in all neonatal cholestasis

• GGT markedly elevated → Consider biliary atresia vs. PFIC3 vs. Alagille syndrome

  • Proceed to imaging (ultrasound, hepatobiliary scintigraphy)
  • Consider liver biopsy: massive duct proliferation suggests PFIC3; bile duct obstruction/plugging suggests biliary atresia
  • Genetic testing for ABCB4 (PFIC3) and JAG1/NOTCH2 (Alagille)

• GGT low or normal → Consider PFIC1 vs. PFIC2 vs. bile acid synthesis defects

  • Check alpha-fetoprotein (very high suggests PFIC2)
  • Assess for extrahepatic features (present in PFIC1)
  • Genetic testing for ATP8B1 (PFIC1) and ABCB11 (PFIC2)
  • Consider bile acid analysis

Step 2: Use additional biochemical markers 3, 6

• Higher ALP and bile acids with lower albumin → favor biliary atresia over metabolic causes
• Very high ALT with elevated AFP → favor PFIC2
• Normal cholesterol → favor PFIC over biliary atresia

Critical Pitfalls to Avoid

1. Do not rely on GGT alone in very young infants: Bile duct paucity in Alagille syndrome may not be evident in early infancy, and GGT patterns can overlap initially 7

2. Timing matters for biliary atresia: Kasai portoenterostomy outcomes are time-dependent; do not delay diagnosis with extensive genetic workup if biliary atresia is suspected clinically

3. PFIC3 can mimic biliary atresia biochemically: Both have high GGT; histology showing massive duct proliferation (rather than obstruction) and genetic testing are essential differentiators 1, 8

4. Some PFIC cases remain genetically undiagnosed: Approximately 10-30% of low-GGT PFIC cases have no identified ATP8B1 or ABCB11 mutations, suggesting additional genetic causes 5, 6

5. CMV infection is more common in biliary atresia (62.5%) than metabolic liver disease (34.6%), which can confound the clinical picture 3

The integration of GGT levels with targeted genetic testing has largely superseded liver biopsy for etiological diagnosis in PFIC 9, though biopsy remains valuable when genetic testing shows variants of uncertain significance or when differentiating PFIC3 from biliary atresia 7.